Bausch + Lomb gives up on glaucoma eye drop hopeful after fail
Fierce Biotech reports: Bausch + Lomb gives up on glaucoma eye drop hopeful after fail.
Bausch + Lomb
NYSE: BLCO $16.17 USD
Bausch + Lomb is a public eye-health company focused on vision care, surgical ophthalmology, and ophthalmic pharmaceuticals.
Company Info
Sector:Eye Health and Ophthalmology
Headquarters:Vaughan, Ontario, Canada
Founded:1853
Website:www.bausch.com/
Recent News
Glaucoma Drug Fails Trial, But Bausch + Lomb Sees Opportunity in Another Eye Disease
Glaucoma Drug Fails Trial, But Bausch + Lomb Sees Opportunity in Another Eye Disease
Leadership Team
Brent Saunders
Chairman and Chief Executive Officer
Careers & Job Openings